AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

562.202

-7.292-1.28%

Number of Gainers:12

Number of Losers:14

Number of Flat:19

PE:- -

High:569.408

Open:567.802

Low:561.923

Close:569.495

Volume:87.51M

Turnover:144.46M

Market Cap:77.09B

Float Cap:74.41B

Loading ...

Mayne Pharma - Several of Company's Branded Dermatology Products May Be Subject to New Section 232 Tariffs

THOMSON REUTERS

CSL Says US Tariffs Unlikely to Impact Plasma-Derived Therapies

MT Newswires Live

CSL Ltd - Initial View Is That Most of CSL's U.S. Product Sales Will Not Be Subject to Tariffs

THOMSON REUTERS

CSL Ltd - Notes Announcement by United States Administration on 2 April

THOMSON REUTERS

CSL Ltd -Effective Date for Any Tariff Impacts Is 29 September 2026

THOMSON REUTERS

CSL Ltd -U.S. Administration Has Recognised Unique Nature of Plasma-Derived Therapies Under Proclamation

THOMSON REUTERS

Malaysia Airlines Strengthens East Asia Network with Return to Fukuoka, Launch of New Routes and Increased Frequencies Across Key Markets

Hexcel (HXL) Valuation Check After Sector Jolt From Iran Energy Hub Threat

Simply Wall St.

Australian Shares Fall Sharply; ASX Commits to Addressing Governance, Risk Management Shortcomings Flagged by ASIC

MT Newswires Live

Is CSL’s Ongoing Share Buy‑Back Reshaping Its Capital Allocation Story for Investors (ASX:CSL)?

Simply Wall St.

Actinogen Medical Launches Buy-Back Under New Employee Share Scheme; Shares Fall 3%

MT Newswires Live

Clinuvel Says Study Shows Repigmentation in Vitiligo Patients After 20 Weeks of Therapy With Drug Candidate; Shares Hit Eight-Year Low

MT Newswires Live

Clinuvel highlights CUV105 vitiligo study case reports showing repigmentation with afamelanotide plus NB-UVB

Mayne Pharma Group Ltd-Non-Executive Director Retirement and Recruitment

THOMSON REUTERS

Paradigm Biopharmaceuticals Partners With UK University for Osteoarthritis Research; Shares Down 4%

MT Newswires Live

Inhibitor Therapeutics sues investor over failed $3 million stock financing

ASX Growth Stocks With High Insider Ownership In April 2026

Simply Wall St.

Watertech China 2026: The Mandatory Global Hub for Water Innovation and Industrial Transformation

Actinogen Medical: in Current Quarter, Co Plans to Meet With Ema to Discuss Opportunities to Streamline Pathway to Xanamem Approval in European Union

THOMSON REUTERS

Actinogen Commences Open-Label Phase of Xanamia Alzheimer’s Trial and Provides Business Update

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":562.20245,"timestamp":1775714399921,"preClose":569.49457,"halted":0,"volume":87513078,"delay":0,"changeRate":-0.012805,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-7.292114,"latestTime":"04-09 16:00:00 AEST","open":567.8019,"high":569.4076,"low":561.9232,"amount":144457119,"amplitude":0.013142,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1775779200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1775692800000,1775714400000]],"turnoverRate":0.003362,"increases":11,"decrements":15,"flats":17,"marketCap":77093809313.25,"floatMarketCap":74406190154.125},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":569.4076,"amplitude":0.013142,"preClose":569.49457,"low":561.9232,"latestPrice":562.20245,"volume":87513078,"delay":0,"open":567.8019,"prevYearClose":644.3692,"prevWeekClose":555.024,"prevMonthClose":565.064,"prevQuarterClose":565.064,"fiveDayClose":565.064,"twentyDayClose":577.544,"sixtyDayClose":653.175,"secType":"PLATE","market":"AU","turnoverRate":0.003362,"marketCap":77093809313.25,"floatMarketCap":74406190154.125,"timestamp":1775714399921,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":12,"down":14,"flat":19},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625460018","title":"Mayne Pharma -  Several of Company's Branded Dermatology Products May Be Subject to New Section 232 Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625460018","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625460018?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:41","pubTimestamp":1775518913,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0KI:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625005846","title":"CSL Says US Tariffs Unlikely to Impact Plasma-Derived Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2625005846","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625005846?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:26","pubTimestamp":1775518017,"startTime":"0","endTime":"0","summary":"CSL  said the US government's new proclamation under section 232 of the trade expansion act on imported pharmaceuticals is unlikely to affect most of its US sales, as its plasma-derived therapies, sourced entirely from American plasma, are considered essential life-saving medicines, according to a Tuesday filing with the Australian bourse.The company continues to invest in US manufacturing and job creation, recently revealing a $1.5 billion plan to expand its plasma therapy production in Illinois, per the filing.The company said that the effective date for any tariff impacts is Sept. 29.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SG9999004303.SGD","SGXZ23171101.USD","CSL","BK7067","BK7508","BK7511","BK7501","LU0728928796.USD","BK4086","CSL.AU","LU1169589451.USD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625760730","title":"CSL Ltd - Initial View Is That Most of CSL's U.S. Product Sales Will Not Be Subject to Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625760730","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625760730?lang=en_us&edition=fundamental","pubTime":"2026-04-07 06:26","pubTimestamp":1775514412,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0MW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","BK7511","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625607300","title":"CSL Ltd -  Notes Announcement by United States Administration on 2 April","url":"https://stock-news.laohu8.com/highlight/detail?id=2625607300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625607300?lang=en_us&edition=fundamental","pubTime":"2026-04-07 06:26","pubTimestamp":1775514412,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0MW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK7511","BK7067","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625535607","title":"CSL Ltd -Effective Date for Any Tariff Impacts Is 29 September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625535607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625535607?lang=en_us&edition=fundamental","pubTime":"2026-04-07 06:26","pubTimestamp":1775514412,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0MW:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","BK7511","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625075826","title":"CSL Ltd -U.S. Administration Has Recognised Unique Nature of Plasma-Derived Therapies Under Proclamation","url":"https://stock-news.laohu8.com/highlight/detail?id=2625075826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625075826?lang=en_us&edition=fundamental","pubTime":"2026-04-07 06:26","pubTimestamp":1775514412,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0MW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","BK7511","CSL.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625161565","title":"Malaysia Airlines Strengthens East Asia Network with Return to Fukuoka, Launch of New Routes and Increased Frequencies Across Key Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2625161565","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625161565?lang=en_us&edition=fundamental","pubTime":"2026-04-05 00:48","pubTimestamp":1775321280,"startTime":"0","endTime":"0","summary":"Resumes services to Fukuoka, Japan from September 2026 after nearly two decades. Expands China footprint with new direct services to Shenzhen and Changsha, commencing July 2026. \"MAG Arena\" showcases Asia's Largest Airline Pavilion at MATTA Fair 2026, featuring the region's premier sports partnership activation by an airline. Increases frequencies across ASEAN, South Asia, Australia and New Zealand and Europe to further strengthen global connectivity. Malaysia Airlines Strengthens East Asia Network with Return to Fukuoka, Launch of New Routes and Increased Frequencies Across Key Markets. Beyond the East Asia expansion, Malaysia Airlines is increasing flight frequencies across key routes namely Brisbane, Australia; Manila, Philippines and Colombo, Sri Lanka to meet rising demand while supporting growing tourism and trade links. In addition, the airline will operate ad-hoc Kuala Lumpur–London flights on 18 and 22 April 2026 to accommodate passengers affected by recent Middle Eastern carr","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2950033/MAG_Arena.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2950033/MAG_Arena.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/malaysia-airlines-strengthens-east-asia-network-with-return-to-fukuoka-launch-of-new-routes-and-increased-frequencies-across-key-markets-302734241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2346227817.USD","BK7096","MYPRF","BK4595","BK4585","BK7508","BK4017","BK4170","IE00BD4GTT62.SGD","IE00BD4GTV84.USD","BK4016","EWM","BK4588","LU1506573853.SGD","IE00B29SXK94.USD","BK7095","BK4600","IE00B29SXL02.USD","BK7067","BK7007","BK7502","IE00B3S45H60.SGD","IE00B775SV38.USD","IE00BSNM7G36.USD","BK4520","BK4526","LU1074936037.SGD","IE00BD4GTW91.USD","IE00BFXG1179.USD","BK4532","BK4006","LU0314106906.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624579539","title":"Hexcel (HXL) Valuation Check After Sector Jolt From Iran Energy Hub Threat","url":"https://stock-news.laohu8.com/highlight/detail?id=2624579539","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624579539?lang=en_us&edition=fundamental","pubTime":"2026-04-02 14:28","pubTimestamp":1775111300,"startTime":"0","endTime":"0","summary":"Geopolitical jolt behind Hexcel’s latest move\nHexcel (HXL) was caught in the market reaction to President Trump’s threat against Iran’s energy infrastructure, including the Kharg Island hub, as investors reassessed risk across aerospace and defense names.\nSee our latest analysis for Hexcel.\nWhile the latest geopolitical shock has put Hexcel back in focus, the stock’s 1 day share price return of 2.05% comes after a 30 day share price return of negative 12.82%. However, its 1 year total...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-hxl/hexcel/news/hexcel-hxl-valuation-check-after-sector-jolt-from-iran-energ","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-hxl/hexcel/news/hexcel-hxl-valuation-check-after-sector-jolt-from-iran-energ","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4131","HUBG","HXL.AU","BK4187","IE00B19Z4B17.USD","IE00B66KJ199.SGD","LU0053671581.USD","LU0205193047.USD","LU0205194284.USD","LU0240877869.USD","BK7508","IE0031619046.USD","LU0240878834.USD","IE00B7SZL793.SGD","HXL","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624313520","title":"Australian Shares Fall Sharply; ASX Commits to Addressing Governance, Risk Management Shortcomings Flagged by ASIC","url":"https://stock-news.laohu8.com/highlight/detail?id=2624313520","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624313520?lang=en_us&edition=fundamental","pubTime":"2026-04-02 13:31","pubTimestamp":1775107900,"startTime":"0","endTime":"0","summary":"Australian shares fell sharply on Thursday's close, the last trading day before the Easter break, after a speech by US President Donald Trump threatened further attacks on Iran.The S&P/ASX 200 Index r","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","ON","XKO.AU","LU1720051108.HKD","BK7067","ASIC","BK7508","SM1.AU","LU1854104046.USD","BK7505","LU2298322129.HKD","XAO.AU","LU1861220033.SGD","BK4107","BK4512","LU0724618433.USD","IE00BFMHRM44.USD","ASX.AU","BK7039","LU1861215975.USD","BK4605","BK7141","LU2360107325.USD","LU1861219969.SGD","IE00BD6J9T35.USD","LU1978683503.SGD","BK4141","BK7509","CUV.AU","LU1720051017.SGD","LU0348723411.USD","LU0124384867.USD","IE00BZ199S13.USD","LU1548497426.USD","LU1854103824.USD","XJO.AU","LU1861214812.USD","BK4588","LU2357305700.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624157969","title":"Is CSL’s Ongoing Share Buy‑Back Reshaping Its Capital Allocation Story for Investors (ASX:CSL)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2624157969","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624157969?lang=en_us&edition=fundamental","pubTime":"2026-04-02 13:29","pubTimestamp":1775107785,"startTime":"0","endTime":"0","summary":"In recent weeks, CSL Limited has continued its on-market buy-back of ordinary shares, repurchasing more than 5.3 million shares as part of its capital management program.\nThis ongoing buy-back underlines CSL’s choice to return capital through reducing its share base, which can enhance per-share financial metrics for remaining investors.\nWe’ll now examine how CSL’s continued on-market buy-back, and its focus on optimising capital structure, may influence the existing investment...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/is-csls-ongoing-share-buyback-reshaping-its-capital-allocati","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/is-csls-ongoing-share-buyback-reshaping-its-capital-allocati","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CSL","BK4211","LU0728928796.USD","BK7067","LU1169589451.USD","SG9999004303.SGD","BK4086","BK7511","BK7508","CSL.AU","ISBC","SGXZ23171101.USD","LU1169590202.USD","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624159521","title":"Actinogen Medical Launches Buy-Back Under New Employee Share Scheme; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624159521","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624159521?lang=en_us&edition=fundamental","pubTime":"2026-04-02 11:00","pubTimestamp":1775098824,"startTime":"0","endTime":"0","summary":"Actinogen Medical  has launched a buy-back of its ordinary fully paid shares under a new employee share scheme, according to a Thursday Australian bourse filing.The company proposed to buy back a maximum of around 2.8 million of its ordinary shares, per the filing.The buy-back is expected to commence on April 28, the filing added.The company's shares fell 3% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACW.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624818521","title":"Clinuvel Says Study Shows Repigmentation in Vitiligo Patients After 20 Weeks of Therapy With Drug Candidate; Shares Hit Eight-Year Low","url":"https://stock-news.laohu8.com/highlight/detail?id=2624818521","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624818521?lang=en_us&edition=fundamental","pubTime":"2026-04-02 10:43","pubTimestamp":1775097809,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) said patient case studies from its ongoing CUV105 study in vitiligo showed repigmentation after 20 weeks of therapy with its drug candidate afamelanotide and adjunct","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CUV.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624652656","title":"Clinuvel highlights CUV105 vitiligo study case reports showing repigmentation with afamelanotide plus NB-UVB","url":"https://stock-news.laohu8.com/highlight/detail?id=2624652656","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624652656?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:37","pubTimestamp":1775093850,"startTime":"0","endTime":"0","summary":"Clinuvel highlighted clinical updates from AAD 2026, where afamelanotide data were already presented across its vitiligo program and its marketed EPP franchise.CUV105 vitiligo case studies presented at meeting showed repigmentation with treatment, with pigment maintenance in darker skin types for up to six months following therapy withdrawal.Long-term EPP analyses presented at AAD supported a consistent safety profile for SCENESSE, with no signal of drug-related malignancies reported across more than 21,000 doses.Management positioned relapse risk on withdrawal of JAK inhibitor therapies as a competitive consideration, citing need for sustained dosing to maintain vitiligo response.Clinuvel introduced an AI-driven Vitiligo Visual Algorithm at conference, with refinement planned to support future study execution including planned CUV107.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and time","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL9w25YF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624331526","title":"Mayne Pharma Group Ltd-Non-Executive Director Retirement and Recruitment","url":"https://stock-news.laohu8.com/highlight/detail?id=2624331526","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624331526?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:33","pubTimestamp":1775093593,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUE1Z01QP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624967523","title":"Paradigm Biopharmaceuticals Partners With UK University for Osteoarthritis Research; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624967523","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624967523?lang=en_us&edition=fundamental","pubTime":"2026-04-02 08:34","pubTimestamp":1775090076,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  partnered with City St George's, University of London, UK, to assess the effects of pentosan polysulfate sodium on bone marrow lesions in osteoarthritis, according to a Thursday filing with the Australian bourse.Pentosan polysulfate sodium is the company's investigational therapy under evaluation in phase three clinical development for knee osteoarthritis, the filing said.The research collaboration is expected to run for about 12 months, per the filing.Paradigm Biopharmaceuticals shares fell 4% in morning trade on Thursday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624491315","title":"Inhibitor Therapeutics sues investor over failed $3 million stock financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624491315","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624491315?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:08","pubTimestamp":1775074095,"startTime":"0","endTime":"0","summary":"Inhibitor Therapeutics filed litigation on March 30, 2026 against an institutional investor tied to a failed financing.Transaction contemplated sale of 12,000,000 common shares at $0.25 per share.Financing also included a warrant to buy up to 7,000,000 additional shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibitor Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL6LspBl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK4139","BK7096","INTI","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624549425","title":"ASX Growth Stocks With High Insider Ownership In April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2624549425","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624549425?lang=en_us&edition=fundamental","pubTime":"2026-04-02 03:08","pubTimestamp":1775070503,"startTime":"0","endTime":"0","summary":"As the Australian market shows signs of recovery with a significant 101-point advance, optimism is building around the potential resolution of Middle East tensions and its positive impact on global indices. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business, aligning well with investor interests during times of economic uncertainty.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/asx-growth-stocks-with-high-insider-ownership-in-april-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/asx-growth-stocks-with-high-insider-ownership-in-april-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FEX.AU","BK7067","AR1.AU","CYC.AU","FRS.AU","AV1.AU","BK7162","BK7508","BK7007","BK7129","BK7062","IMA.AU","BK7005","PNV.AU","BK7016","BK7110","MAU.AU","DVP.AU","BK7095","BK7104","XJO.AU","BK7126","XAO.AU","XKO.AU","EIQ.AU","TOR.AU","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624511914","title":"Watertech China 2026: The Mandatory Global Hub for Water Innovation and Industrial Transformation","url":"https://stock-news.laohu8.com/highlight/detail?id=2624511914","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624511914?lang=en_us&edition=fundamental","pubTime":"2026-04-01 21:35","pubTimestamp":1775050500,"startTime":"0","endTime":"0","summary":"WATERTECH CHINA 2026: 18th Shanghai International Water Show, June 9-11, at NECC Shanghai . The 2026 edition will expand to a massive 180,000 sqm, hosting over 2,500 exhibitors and attracting more than 100,000 professional visitors from 175 countries and regions. Covering the entire water value chain, the exhibition serves 28 end-user industries—from municipal infrastructure to industrial manufacturing—acting as a high-efficiency B2B gateway for global procurement and strategic partnerships.Strategic Global MatchmakingTo maximize business impact, the international matchmaking program will connect over 500 leading brands with 10,000 targeted international buyers. To facilitate global participation, the organizers provide comprehensive support, including invitation letters and visa assistance for eligible overseas attendees.Call to ActionAs water management continues to play an increasingly important role in public health, industrial development and sustainability, WATERTECH CHINA 2026 w","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2947806/1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2947806/1.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/watertech-china-2026-the-mandatory-global-hub-for-water-innovation-and-industrial-transformation-302731411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4131","IE00B19Z4B17.USD","HUBG","IE00B66KJ199.SGD","ZLD.AU","IE0031619046.USD","BK7502","BK7508","BK7096","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624515941","title":"Actinogen Medical: in Current Quarter, Co Plans to Meet With Ema to Discuss Opportunities to Streamline Pathway to Xanamem Approval in European Union","url":"https://stock-news.laohu8.com/highlight/detail?id=2624515941","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624515941?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:30","pubTimestamp":1775046600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUA53THZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","ACW.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624515556","title":"Actinogen Commences Open-Label Phase of Xanamia Alzheimer’s Trial and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624515556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624515556?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:30","pubTimestamp":1775046600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUA53THZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ACW.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":88,"code":"91000000","status":"200"}]}}